Getinge AB stock (SE0000202624): acquisition of Pennamed sharpens endoscopy focus

Swedish medtech group Getinge AB is expanding its endoscopy footprint with the acquisition of UK-based distributor Pennamed. The deal aims to strengthen Getinge’s consumables offering for NHS and private hospitals and could deepen its presence in a key European healthcare market.

Getinge AB is reinforcing its position in minimally invasive care: on May 15, 2026, the Swedish medical technology group announced the acquisition of Pennamed, a UK-based distributor of endoscopic consumables serving the National Health Service (NHS) and independent hospitals, according to Getinge press release as of 05/15/2026. The transaction is intended to bolster Getinge’s offering in flexible endoscopy and strengthen customer access in the important UK market.

As of: 20.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Getinge B
• Sector/industry: Medical technology, hospital equipment
• Headquarters/country: Gothenburg, Sweden
• Core markets: Intensive care, operating rooms, sterile reprocessing, life science
• Key revenue drivers: Ventilators, surgical workflow solutions, sterilizers, service and consumables
• Home exchange/listing venue: Nasdaq Stockholm (ticker: GETI B)
• Trading currency: Swedish krona (SEK)

Getinge AB: core business model

Getinge AB focuses on equipment, consumables and services that support acute care and surgical workflows in hospitals and laboratories. The company’s portfolio covers intensive care ventilators, anesthesia machines, operating tables and lights, perfusion systems for cardiac surgery and sterile reprocessing solutions that help hospitals maintain instrument hygiene and patient safety.

The business is typically organized into areas such as acute care therapies and surgical workflows, complemented by a growing life science segment. Acute care therapies include mechanical ventilators and devices that support critically ill patients, while surgical workflows encompass planning software, tables, lamps and ceiling supply units. Life science products cater to research laboratories and biopharma customers that require contamination control and sterilization.

Getinge’s business model combines capital equipment sales with recurring revenue from consumables, service contracts and software. Once installed, devices such as ventilators, washer-disinfectors and sterilizers require regular maintenance, spare parts and validation services, which can generate a stable, higher-margin revenue stream over the life cycle of the equipment. This mix of upfront sales and recurring income is typical for large medtech suppliers to hospital systems.

The Pennamed acquisition fits into this model by strengthening the consumables and accessories side of the endoscopy offering. Endoscopic procedures rely on a steady flow of single-use items and specialized tools. By bringing a local distributor with established customer relationships into the group, Getinge seeks to ensure closer proximity to UK hospitals, potentially improving logistics, service levels and cross-selling opportunities within its broader portfolio.

Main revenue and product drivers for Getinge AB

In acute care, Getinge is widely known for its Servo line of intensive care ventilators. These devices are used to support patients with respiratory failure in intensive care units, and they contribute meaningfully to the company’s revenue, particularly in markets such as the United States, where demand for advanced ventilators is significant. An industry overview of the U.S. ventilator market up to 2034 highlights Getinge as a notable contributor through its Servo platform, according to Market Data Forecast as of 02/12/2024.

Surgical workflows represent another major revenue pillar. Getinge supplies operating tables, lights, modular OR solutions and ceiling supply units that organize power and gas in the operating room. These systems are often sold as integrated projects during hospital construction or renovation. Once in place, they create a base for ongoing service, upgrades and software sales, enabling Getinge to maintain long-term relationships with hospital networks and procurement authorities.

Sterile reprocessing and infection control products also play a key role in Getinge’s revenue profile. Hospitals rely on washer-disinfectors, sterilizers and related automation to reprocess surgical instruments and endoscopes safely. Demand in this area tends to be driven by regulatory requirements and hospital-acquired infection control standards. Market research discussing hospital-acquired infection control suggests that companies like Getinge, along with other global suppliers, benefit from stricter hygiene and quality protocols, according to Future Market Insight as of 09/18/2023.

The newly acquired Pennamed business is focused on endoscopic consumables rather than large capital equipment. These products are typically used in diagnostic and therapeutic procedures in gastroenterology and other specialties. Because they are replaced frequently, they can provide a recurring revenue stream less dependent on capital budgeting cycles. Integrating this range into Getinge’s established product lines could help balance the group’s portfolio between large equipment sales and consumables.

Geographically, Getinge generates revenue across Europe, North America, Asia-Pacific and other regions, with the U.S. often representing a substantial portion of sales due to the size and spending power of its hospital market. The focus on products such as ventilators, surgical tables and sterile reprocessing systems gives the company exposure to long-term structural trends like an aging population, rising procedure volumes and increased focus on infection prevention in advanced healthcare systems.

Industry trends and competitive position

The markets in which Getinge operates are characterized by high regulatory barriers, long product approval cycles and a strong emphasis on reliability and service. Competitors include large diversified medtech groups and specialized players in ventilators, operating rooms and infection control. In infection control, major global brands from North America and Europe compete for hospital tenders, often offering bundled equipment and service packages. This competitive context explains why scale, local presence and long-term service capabilities are important differentiators.

At the same time, hospitals and health systems face pressure to manage costs, optimize bed utilization and reduce complications such as hospital-acquired infections. These pressures drive demand for efficient workflows, automated reprocessing solutions and advanced monitoring in the OR and ICU. Getinge’s portfolio is aligned with these needs, with systems designed to improve throughput, support standardization of procedures and facilitate documentation. The Pennamed acquisition suggests that the company is also keen to deepen its role in the consumables segment, where product availability and supply reliability are crucial for daily operations.

In the endoscopy space, where Pennamed is active, demand is influenced by screening programs, demographic trends and the shift toward minimally invasive procedures. Hospitals often prefer suppliers that can provide both equipment and a reliable pipeline of tailored consumables. By adding a UK distributor specialized in endoscopy consumables, Getinge appears to be expanding its ability to serve endoscopy units with a broader offering and stronger local support, which may sharpen its competitive position in this procedure-driven market.

Why Getinge AB matters for US investors

For US-based investors, Getinge AB represents exposure to a global medtech supplier that operates in critical hospital infrastructure segments. Its ventilators, sterilizers and OR solutions are used in advanced healthcare systems worldwide, including in the United States. This gives the company a footprint in a market with high per-capita healthcare spending and ongoing investments in hospital capacity and technology.

The stock is listed on Nasdaq Stockholm in Swedish krona, which introduces currency considerations for dollar-based investors and access via international trading platforms or depositary receipt structures, depending on broker offerings. At the same time, the company’s revenue base spans multiple regions and currencies, providing diversification relative to purely domestic US healthcare names. For some investors, this combination of global hospital exposure and European listing may serve as a complement to large US medtech holdings.

The Pennamed acquisition underlines Getinge’s focus on deepening its portfolio in procedural and consumable-driven areas that can generate recurring sales. For investors following global trends in minimally invasive procedures, infection control and ICU care, such moves provide insight into how the company is positioning its product mix and regional presence. Observers in the US market may watch how Getinge balances investments between developed markets like the UK and North America and faster-growing regions.

Conclusion

The acquisition of Pennamed highlights how Getinge AB continues to refine its portfolio around endoscopy and hospital workflows, complementing its established strengths in ventilators, surgical environments and sterile reprocessing. For investors, the move illustrates a strategy of combining capital equipment with consumables and service, potentially enhancing recurring revenue and customer stickiness in key markets. At the same time, the company operates in a competitive and highly regulated sector, where tenders, reimbursement conditions and capital spending cycles can influence results. As with all medtech stocks, a balanced view of opportunities in minimally invasive procedures and infection control, alongside the associated operational and market risks, remains important when following Getinge’s equity story.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.